<DOC>
	<DOCNO>NCT00243854</DOCNO>
	<brief_summary>To determine feasibility toxicity neoadjuvant hypofractioned radiotherapy concurrently weekly gemcitabine EGFR tyrosine-kinase inhibitor ( OSI-774 , Tarceva ) treatment patient resectable pancreatic cancer .</brief_summary>
	<brief_title>Pilot Study Using Neoadj Chemo-Rad &amp; EGFR-tyrosine Kinase Inhibitor Potentially Resectable Pancreatic Cancer</brief_title>
	<detailed_description>To determine feasibility toxicity neoadjuvant hypofractioned radiotherapy concurrently weekly gemcitabine EGFR tyrosine-kinase inhibitor ( OSI-774 , Tarceva ) treatment patient resectable pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>pathologically confirm adenocarcinoma pancreas resectable disease tumor &lt; /= 6cm diameter ECOG performance 01 Organ system fxn : granulocyte ( &gt; /=1800/uL ) ; plt ct &gt; /=100K ; bili &lt; /=2mg ; liver enzymes &lt; 2.5ULN ; crt &lt; /=1.5 ; Normal CXR Negative pregnancy test metastatic disease peritoneal seed base crosssectional image previous irradiation plan field prior chemotherapy immunotherapy active infection active PUD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Resectable Pancreatic Cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>